All Stories

  1. The influence of time horizon on results of cost-effectiveness analyses

    Article • Expert Review of Pharmacoeconomics & Outcomes Research, May 2017, Taylor & Francis

    David Kim, Dr James D Chambers

  2. Docetaxel chemotherapy in metastatic castration-resistant prostate cancer: cost of care in Medicare and commercial populations

    Article • Current Medical Research and Opinion, April 2017, Taylor & Francis

    Dr James D Chambers

  3. The decline in vitamin research funding: A missed opportunity?

    Article • Current Developments in Nutrition, April 2017, American Society for Nutrition

    Dr James D Chambers, Professor Keith P West

  4. Medicare Is Scrutinizing Evidence More Tightly For National Coverage Determinations

    Article • Health Affairs, February 2015, Health Affairs

    Dr James D Chambers

  5. Despite High Costs, Specialty Drugs May Offer Value For Money Comparable To That Of Traditional Drugs

    Article • Health Affairs, October 2014, Health Affairs

    Ms Teja Thorat, Dr James D Chambers

  6. Medicare Covers The Majority Of FDA-Approved Devices And Part B Drugs, But Restrictions And Discrepancies Remain

    Article • Health Affairs, June 2013, Health Affairs

    Dr James D Chambers

  7. Therapies For Advanced CancersPose A Special Challenge For Health Technology Assessment Organizations In Many Countries

    Article • Health Affairs, April 2012, Health Affairs

    Dr James D Chambers

  8. Risk-Sharing Arrangements That Link Payment For Drugs To Health Outcomes Are Proving Hard To Implement

    Article • Health Affairs, December 2011, Health Affairs

    Dr James D Chambers